Boehringer Ingelheim has entered into a multi-year strategic partnership with TARGET PharmaSolutions, a real-world clinical data company, for an observational study TARGET-NASH.
This study is evaluating patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH) and has enrolled 2,423 patients at 55 sites, with the expectation to enroll as many as 15,000 patients over the coming years.
The TARGET model organizes a community of stakeholders, including pharmaceutical manufacturers, key opinion leaders, regulatory agencies, investigators, and patient advocacy groups, around a specific disease to generate real world evidence about the natural history of the given disease, current treatment paradigm, and patient outcomes.
Meg Powell, chief executive officer of TARGET PharmaSolutions, said, "We are very excited to have Boehringer Ingelheim join TARGET-NASH as an industry partner. We have exceeded our enrollment targets to date, and we are providing valuable real-world data and insight on NASH patients that will have a significant impact on the scientific understanding of the natural history and treatment modalities for NASH. This data, combined with the TARGET-NASH biorepository and patient reported outcomes, will enable our collaborators to continue to increase their understanding of this growing disease."
Breaking News
Boehringer, TARGET Pharma in Strategic NASH Pact
Observational study to incorporate TARGET model of community of stakeholders
10.19.17
Related Breaking News
-
Breaking News | Industry News | Information Technology
FDA Purchases Software from Waters to Support its Medical Testing Labs
Will speed data retrieval, automate essential audit and archival functions, and ensure compliance with legislative mandates.01.26.22
-
Breaking News | cGMP Manufacture | Information Technology
Colorcon Ventures Invests in Intelligent Pharma Mfg. System Provider
Apprentice platform designed to streamline batch-based manufacturing and remote collaboration.01.21.22
-
Breaking News | Clinical Trial Materials | Clinical Trials | Collaborations & Alliances | Industry News
Altasciences and Virpax Pharmaceuticals Enter Clinical Trial Partnership
Altasciences to conduct first-in-human study of Epoladerm for chronic pain associated with osteoarthritis of the knee.01.21.22
-
Breaking News | Clinical Trials
FDA Agrees to Use of New Manufacturing Process for Nomacopan in Clinical Studies
New manufacturing process increases the final yield of nomacopan at least five-fold, compared to the previous process.01.19.22
-
Breaking News | Industry News | Information Technology
Colorcon Ventures Invests in Bio-Simulation Startup VeriSIM Life
VeriSIM’s platform accelerates drug development and reduces animal testing.01.18.22
-
Bio News | Breaking News | Clinical Trials | CRO News | Industry News | R&D
Cato SMS, Pharm-Olam Merge to Create Global Biopharma Services Company
Newly combined company positioned to serve small and mid-sized biopharmaceutical companies.01.07.22
-
Breaking News | Clinical Trials
Pentarlandir Proves Effective Against COVID-19 Variants in Preclinical Studies
Costs for the drug are expected to be significantly lower than for Pfizer’s Paxlovid.01.06.22
-
Breaking News | Clinical Trials | Drug Development | Trials & Filings
Jubilant Therapeutics Receives FDA Clearance for JBI-802 IND
Phase 1/2a trial designed to define the safety profile and preliminary activity of JBI-802 in participants with advanced solid tumors.01.06.22
-
Breaking News | Clinical Trials | Collaborations & Alliances
Synairgen Partners with Ashfield Engage to Support the Commercialization of SNG001
Aims to bring innovative potential treatment to COVID-19 patients.01.06.22
-
Biologics, Proteins, Vaccines | Breaking News | Clinical Trials | Collaborations & Alliances | Industry News
Nasal Spray Corona Vaccine Enters Clinical Trial
Leiden Medical Center and Intravacc to start clinical trial with new intranasal corona vaccine.01.05.22
-
Breaking News | Clinical Trials
Evotec Receives German Grant for Potential Therapy Against COVID-19
Under the grant, Evotec will initiate the clinical development of a potentially highly potent immunomodulatory molecule.01.04.22
-
Breaking News | Clinical Trials | CRO News | Information Technology
Emmes Acquires CRO Institut Dr. Schauerte
Full-service, technology-oriented CRO specializes in late-phase, non-interventional, and post-market clinical follow-up studies.01.04.22
-
Breaking News | Clinical Trials | Collaborations & Alliances | Drug Development
Evofem Biosciences, Orion Biotechnology Enter OB-002 Alliance
To evaluate Orion's CCR5 antagonist, OB-002, in Evofem's Phexxi vaginal gel with the goal of developing a Multipurpose Prevention Technology for HIV.12.20.21
-
Biologics, Proteins, Vaccines | Breaking News | Clinical Trials | Drug Development | Industry News
ProBioGen’s GlymaxX Technology Reaches Phase III Development
Zymeworks recently announced a global Phase III clinical trial of zanidatamab in HER2‑expressing gastroesophageal cancer.12.17.21
-
Breaking News | Clinical Trials
FDA Accepts Rakuten Medical’s IND Application for Oncology Candidate
Will begin clinical studies of RM-1995 photoimmunotherapy in advanced head and neck cancer.12.16.21
